This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Joel Blankson, MD, PhD; Robert F. Siliciano, MD, PhD

JAMA. 2000;284:236-238.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Approaches to the treatment of human immunodeficiency virus type 1 (HIV-1) infection continue to evolve rapidly, raising complex medical and scientific questions. The advent of highly active antiretroviral therapy (HAART), involving combinations of inhibitors of HIV-1 reverse transcriptase and protease, has resulted in dramatic decreases in death rates from acquired immunodeficiency syndrome (AIDS) in the United States.¹ In select patient populations participating in clinical trials of various HAART regimens, clearance of detectable virus from blood is observed in 70% to 90% of patients.^2-4 Patients who respond to HAART show a surprising degree of reconstitution of the immune system.

Even though HAART represents a truly inspiring example of the success of rational drug design, there certainly are downsides associated with this therapeutic approach. In a typical urban clinic, response rates to HAART may be only 35% to 40%.⁵ An increasing number of . . . [Full Text of this Article]

Author Affiliations: Johns Hopkins University School of Medicine, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy: A Randomized Controlled Trial
Richard T. Davey, Jr, Robert L. Murphy, Frank M. Graziano, Stephen L. Boswell, Andrew T. Pavia, Margarita Cancio, Jeffrey P. Nadler, Doreen G. Chaitt, Robin L. Dewar, David K. Sahner, Anne-Marie Duliege, William B. Capra, Wai-Ping Leong, Martin A. Giedlin, H. Clifford Lane, and James O. Kahn
JAMA. 2000;284(2):183-189.
ABSTRACT | FULL TEXT  

Immune Restoration With Antiretroviral Therapies: Implications for Clinical Management
Michael M. Lederman and Hernan Valdez
JAMA. 2000;284(2):223-228.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory
Saavedra-Lozano et al.
Proc. Natl. Acad. Sci. USA 2004;101:2494-2499.
ABSTRACT | FULL TEXT  

The Role of Interleukin-2 in HIV Treatment
JWatch General 2000;2000:2-2.
FULL TEXT